CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|November 1, 2006
Drug Watch: Agents in late-stage development for the treatment of juvenile idiopathic, psoriatic, and rheumatoid arthritis (November 2006) (PDF)
Review of agents in late-stage development for the treatment of juvenile idiopathic, psoriatic, and rheumatoid arthritis (November 2006).
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
High prices and cutbacks in ACA and Medicaid coverage leave many patients unable to medical bills.
In this discussion, Heather Burrell-Ward, M.D., provides an overview of her recent study that found TMS aimed at the default mode network improved processing speed in schizophrenia.
Rand researchers identify standardizing supplemental benefits, limiting the number of plans an insurer can market and reforming broker commissions as policy proposals that would benefit beneficiaries while not harming the government or the plans.
Reimagine Care and Dan Nardi scale CAR-T programs with remote cancer care, AI triage and nurses, as the Cureety partnership tackles staffing and access.
Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier drugs, says Christine Johnston.
Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Christine Johnston on why biosimilars are losing formulary ground
2
Medicare Advantage needs fixing. Here are 3 feasible repairs
3
Dan Nardi of Reimagine Care discusses how to help community practices scale CAR-T programs
4
A conversation with Heather Burrell Ward, M.D., about developing TMS as a treatment for the cognitive symptoms of schizophrenia
5